



PRIOR AUTHORIZATION POLICY

POLICY: Migraine – Calcitonin Gene-Related Peptide Inhibitors – Ajovy Prior Authorization Policy

- Ajovy® (fremanezumab-vfrm subcutaneous injection – Teva)

REVIEW DATE: 04/22/2026

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Ajovy, a calcitonin gene-related peptide (CGRP) antagonist, is indicated for the **preventive treatment of migraine** in adults and the **preventive treatment of episodic migraine in pediatric patients** who are 6 to 17 years of age and who weigh ≥ 45 kg.¹

Disease Overview

Migraines have been defined as chronic or episodic. Chronic migraine is described by the International Headache Society as headache occurring on ≥ 15 days/month for > 3 months and has the features of migraine headache on ≥ 8 days/month.² Episodic migraine is characterized by headaches that occur < 15 days/month.^{3,4} Episodic migraine is more common than chronic migraine; however, chronic migraine is associated with a markedly greater personal and societal burden.

Guidelines

An updated assessment of the **preventive and acute treatment of migraine** by the **American Headache Society** (AHS) [2018; update 2021] reaffirms previous migraine guidelines.^{5,6} Patients with migraine should be considered for preventive treatment in the following situations: when attacks significantly interfere with patients' daily routines despite acute treatment; frequent attacks (≥ 4 monthly headache days); at least moderate disability (Migraine Disability Assessment [MIDAS] score ≥ 11 or six-item Headache Impact Test [HIT-6] score > 50); contraindication to, failure, overuse, or adverse events with acute treatments; or patient preference. The choice of preventive treatment should be based on an individual's history of response to acute and preventive therapies, evidence of efficacy, tolerability, prescriber professional experience, headache subtype, comorbidities/coexistent disease, concomitant medications, patient's potential for childbearing, and patient preference. Before developing a preventive treatment plan, the appropriate use (e.g., drug type, route and timing of administration, frequency) of acute treatments should be initiated and coupled with education and lifestyle modifications. All patients with migraine should be offered a trial of acute treatment. Based on the level of evidence for efficacy and the American Academy of Neurology scheme for classification of evidence, the following oral treatments have established efficacy and should be offered for migraine prevention: antiepileptic drugs (**divalproex sodium, valproate sodium, topiramate**; not for women of childbearing potential without a reliable method of birth control); beta-blockers (**metoprolol, propranolol, timolol**); **candesartan**; and **frovatriptan** (for short-term preventive treatment of menstrual migraine). Parenteral therapies that have established efficacy in the prevention of migraines are **CGRP monoclonal antibodies** (Aimovig[®] [erenumab-aooe subcutaneous {SC} injection], Ajovy[®] [fremanezumab-vfrm SC injection], Emgality[®] [galcanezumab-gnlm SC injection], and Vyepti[®] [eptinezumab-jjmr intravenous infusion]), and **Botox[®] (onabotulinumtoxinA)**. The following treatments are probably effective and should be considered for migraine prevention: antidepressants (**amitriptyline, venlafaxine**); beta-blockers (**atenolol, nadolol**); and **lisinopril; memantine; and Botox + CGRP monoclonal antibody**.

The **AHS** issued an update to their position statement (2024) specifically regarding therapies targeting CGRP for the prevention of migraine.⁷ The evidence for the efficacy, tolerability, and safety of CGRP-targeting migraine-preventive therapies (specifically, the monoclonal antibodies: Aimovig, Ajovy, Emgality, and Vyepti, and the gepants: Nurtec[®] ODT [rimegepant orally disintegrating tablets] and Qulipta[®] [atogepant tablets]) is substantial and consistent across different individual CGRP-targeting treatments. Extensive "real-world" clinical experience corroborates clinical trials. These data indicate that the efficacy and tolerability of CGRP-targeting therapies are equal to or greater than those of previous first-line therapies. The CGRP-targeting therapies are considered as first-line options for migraine prevention along with other first-line treatments.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Ajovy. All approvals are provided for the duration noted below.

• **Ajovy® (fremanezumab-vfrm subcutaneous injection – Teva)** is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indications

1. Migraine Headache Prevention in Adults. Approve for 1 year if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve if the patient meets BOTH of the following (i and ii):

- i.** Patient is ≥ 18 years of age; AND
- ii.** Patient has ≥ 4 migraine headache days per month (prior to initiating a migraine-preventive medication); OR

B) Patient is Currently Receiving Ajovy. Approve if the patient meets ALL of the following (i, ii, and iii):

- i.** Patient is ≥ 18 years of age; AND
- ii.** Patient has ≥ 4 migraine headache days per month (prior to initiating a migraine-preventive medication); AND
- iii.** Patient has had a significant clinical benefit from the medication, as determined by the prescriber.

Note: Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Ajovy was initiated.

2. Preventive Treatment of Episodic Migraine in Pediatric Patients. Approve for 1 year if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve if the patient meets BOTH of the following (i and ii):

- i.** Patient is ≥ 6 years of age and < 18 years of age; AND
- ii.** Patient has ≥ 4 and < 15 migraine headache days per month (prior to initiating a migraine-preventive medication); OR

B) Patient is Currently Receiving Ajovy. Approve if the patient meets ALL of the following (i, ii, and iii):

- i.** Patient is ≥ 6 years of age and < 18 years of age; AND
- ii.** Patient has ≥ 4 and < 15 migraine headache days per month (prior to initiating a migraine-preventive medication); AND
- iii.** Patient has had a significant clinical benefit from the medication as determined by the prescriber.

Note: Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Ajovy was initiated.

CONDITIONS NOT COVERED

• **Ajovy® (fremanezumab-vfrm subcutaneous injection – Teva)** is(are) considered not medically necessary for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

- 1. Acute Treatment of Migraine.** Ajovy has not been studied for the acute treatment of migraine.
- 2. Cluster Headache, Treatment or Prevention.** Ajovy has not been found to be effective in Phase III clinical trials in patients with episodic and chronic cluster headache.⁸
- 3. Concurrent Use with Another Calcitonin Gene-Related Peptide (CGRP) Inhibitor Being Prescribed for Migraine Headache Prevention.**
Note: CGRP inhibitors that are indicated for migraine headache prevention include Aimovig (erenumab-aooe subcutaneous injection), Emgality (galcanezumab-gnlm subcutaneous injection), Vyepti (eptinezumab-jjmr intravenous infusion), and Qulipta (atogepant tablets). Ajovy, Aimovig, Emgality, and Vyepti are injectable CGRP inhibitors for migraine prevention and have not been studied for use in combination with another agent in the same class.⁹⁻¹¹ Qulipta is an oral CGRP inhibitor for the preventive treatment of migraine in adults.¹²
- 4. Concurrent Use with Nurtec ODT (rimegepant sulfate orally disintegrating tablet) When Used as a Preventive Treatment of Episodic Migraine.** Nurtec ODT is an oral CGRP inhibitor for the acute treatment of migraine and for the preventive treatment of episodic migraine in adults.¹³

REFERENCES

1. Ajovy® subcutaneous injection [prescribing information]. North Wales, PA: Teva; August 2025.
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 3rd edition. *Cephalalgia*. 2018;38:1-211.
3. Damen JAA, Yang B, Idema DL, et al. Comparative effectiveness of pharmacologic treatments for the prevention of episodic migraine headache: A systematic review and network meta-analysis for the American College of Physicians. *Ann Intern Med*. 2025;178(3):369-380.
4. Burch R. Chronic migraine in adults. *JAMA*. 2025;333(5):423-424.
5. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59:1-18.
6. Ailani J, Burch RC, Robbins MS, on behalf of the Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. *Headache*. 2021;00:1-19.
7. Charles AC, Digre KB, Goadsby PJ, et al. American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. *Headache*. 2024;64(4):333-341.
8. Teva announces update on fremanezumab clinical development for use in episodic cluster headache [press release]. North Wales, PA: Teva Pharmaceuticals USA; April 23, 2019. Available at: <https://www.tevapharm.com/news-and-media/latest-news/>. Accessed on April 14, 2026.
9. Aimovig® subcutaneous injection [prescribing information]. Thousand Oaks, CA: Amgen; March 2025.
10. Emgality® subcutaneous injection [prescribing information]. Indianapolis, IN: Lilly; October 2025.
11. Vyepti® intravenous infusion [prescribing information]. Bothell, WA: Lundbeck; October 2025.
12. Qulipta® tablets [prescribing information]. North Chicago, IL: AbbVie; September 2025.

13. Nurtec® ODT [prescribing information]. New York, NY: Pfizer; March 2026.

HISTORY

Type of Revision	Summary of Changes	Review Date
Early Annual Revision	Migraine Headache Prevention: The criteria requiring a patient to have tried at least two standard prophylactic (preventive) pharmacologic therapies, each from a different pharmacologic class, and requiring that a patient has had inadequate efficacy or adverse event(s) severe enough to warrant discontinuation of those therapies have been removed.	04/10/2024
Annual Revision	No criteria changes.	04/16/2025
Selected Revision	Migraine Headache Prevention in Adults: The approval condition was modified to include "in Adults." Preventive Treatment of Episodic Migraine in Pediatric Patients: This was added as a new condition of approval.	08/13/2025
Annual Revision	Migraine Headache Prevention in Adults: Existing requirements were reformatted into separate sets of requirements for Initial Therapy and Continuation of Therapy. Preventive Treatment of Episodic Migraine in Pediatric Patients: Existing requirements were reformatted into separate sets of requirements for Initial Therapy and Continuation of Therapy.	04/22/2026

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.